OBJECTIVE: The purpose of this study was to evaluate whether high mammographic density can be used as one of the selection criteria for MRI in invasive lobular breast cancer (ILC). METHODS: In our institute, high breast density has been used as one of the indications for performing MRI scan in patients with ILC. We divided the patients in two groups, one with MRI performed pre-operatively and other without MRI. We compared their surgical procedures and analyzed whether surgical plan was altered after MRI. In case of alteration of plan, we analyzed whether the change was adequate by comparing post-operative histological findings. RESULTS: Between 2011 and 2015, there were a total of 1601 breast cancers with 97 lobular cancers, out of which 36 had pre-operative MRI and 61 had no MRI scan. 12 (33.3%) had mastectomy following MRI, out of which 9 (25%) had change in surgical plan from conservation to mastectomy following MRI. There were no unnecessary mastectomies in the MRI group. However, utilization of MRI in this cohort of patients did not reduce reoperation rate (19.3%). Lobular carcinoma in situ (LCIS) was identified in 60% of reoperations on post-surgical histology. Patients in the "No MRI" group had higher mastectomy rate 26 (42.6%), which was again appropriate. CONCLUSION: High mammographic density is a useful risk stratification criterion for selective MRI in ILC within a multidisciplinary team meeting setting. Provided additional lesions identified on MRI are confirmed with biopsy, pre-operative MRI does not cause unnecessary mastectomies. Used in this selective manner, reoperation rates were not eliminated, albeit reduced when compared to literature. ADVANCES IN KNOWLEDGE: High mammographic breast density can be used as one of the selection criteria for pre-operative MRI in ILC without an increase in inappropriate mastectomies with potential time and cost savings. In this cohort, re-excisions were not reduced markedly with pre-operative MRI.
OBJECTIVE: The purpose of this study was to evaluate whether high mammographic density can be used as one of the selection criteria for MRI in invasive lobular breast cancer (ILC). METHODS: In our institute, high breast density has been used as one of the indications for performing MRI scan in patients with ILC. We divided the patients in two groups, one with MRI performed pre-operatively and other without MRI. We compared their surgical procedures and analyzed whether surgical plan was altered after MRI. In case of alteration of plan, we analyzed whether the change was adequate by comparing post-operative histological findings. RESULTS: Between 2011 and 2015, there were a total of 1601 breast cancers with 97 lobular cancers, out of which 36 had pre-operative MRI and 61 had no MRI scan. 12 (33.3%) had mastectomy following MRI, out of which 9 (25%) had change in surgical plan from conservation to mastectomy following MRI. There were no unnecessary mastectomies in the MRI group. However, utilization of MRI in this cohort of patients did not reduce reoperation rate (19.3%). Lobular carcinoma in situ (LCIS) was identified in 60% of reoperations on post-surgical histology. Patients in the "No MRI" group had higher mastectomy rate 26 (42.6%), which was again appropriate. CONCLUSION: High mammographic density is a useful risk stratification criterion for selective MRI in ILC within a multidisciplinary team meeting setting. Provided additional lesions identified on MRI are confirmed with biopsy, pre-operative MRI does not cause unnecessary mastectomies. Used in this selective manner, reoperation rates were not eliminated, albeit reduced when compared to literature. ADVANCES IN KNOWLEDGE: High mammographic breast density can be used as one of the selection criteria for pre-operative MRI in ILC without an increase in inappropriate mastectomies with potential time and cost savings. In this cohort, re-excisions were not reduced markedly with pre-operative MRI.
Authors: N van den Broek; M J C van der Sangen; L V van de Poll-Franse; M W P M van Beek; G A P Nieuwenhuijzen; A C Voogd Journal: Breast Cancer Res Treat Date: 2006-11-18 Impact factor: 4.872
Authors: Lawrence J Solin; Susan G Orel; Wei-Ting Hwang; Eleanor E Harris; Mitchell D Schnall Journal: J Clin Oncol Date: 2008-01-20 Impact factor: 44.544
Authors: Rajini Katipamula; Amy C Degnim; Tanya Hoskin; Judy C Boughey; Charles Loprinzi; Clive S Grant; Kathleen R Brandt; Sandhya Pruthi; Christopher G Chute; Janet E Olson; Fergus J Couch; James N Ingle; Matthew P Goetz Journal: J Clin Oncol Date: 2009-07-27 Impact factor: 44.544
Authors: Richard J Bleicher; Robin M Ciocca; Brian L Egleston; Linda Sesa; Kathryn Evers; Elin R Sigurdson; Monica Morrow Journal: J Am Coll Surg Date: 2009-06-18 Impact factor: 6.113
Authors: Brian M Moloney; Peter F McAnena; Éanna J Ryan; Ellen O Beirn; Ronan M Waldron; AnnaMarie O Connell; Sinead Walsh; Rachel Ennis; Catherine Glynn; Aoife J Lowery; Peter A McCarthy; Michael J Kerin Journal: Breast Cancer (Auckl) Date: 2020-08-14
Authors: Habib Rahbar; Daniel S Hippe; Ahmed Alaa; Safia H Cheeney; Mihaela van der Schaar; Savannah C Partridge; Christoph I Lee Journal: Radiol Imaging Cancer Date: 2020-07-10
Authors: Thiemo Ja van Nijnatten; Maxine S Jochelson; Katja Pinker; Delia M Keating; Janice S Sung; Monica Morrow; Marjolein L Smidt; Marc Bi Lobbes Journal: BJR Open Date: 2019-03-11